Europe does not have one psychedelic law. This guide compares Portugal’s decriminalization model, the Netherlands’ mushroom and truffle distinction, and Switzerland’s exceptional medical and research licensing system.

A current global guide to the difference between legalization, decriminalization, medical access and research access for psilocybin, LSD and MDMA, with examples from Australia, Switzerland, Portugal, the Netherlands, Canada and Brazil.

A current, evidence-informed overview of Canadian law on psilocybin mushrooms, LSD and MDMA, including the federal CDSA, British Columbia’s expired decriminalization pilot, Alberta’s psychedelic-treatment licensing framework, and legal clinical-access pathways.